The Effect of Conduction Exercise and Self-Acupressure in Treatment of Parkinson’s Disease: A Pilot Study
Table 3
Secondary outcomes across study time points.
CE and SA group (N = 22)
Control group (N = 14)
Between group
Mean ± SE
Mean ± SE
Adjusted mean difference ± SE (95% CI)
value†
Secondary outcome CDQ
Total
Baseline
Week 4
38.41 ± 5.43
27.00 ± 6.28
Week 8
40.68 ± 5.67
38.17 ± 6.51
−4.24 ± 4.00 (−12.38 to 3.90)
0.30
Sleep/fatigue
33.45 ± 5.86
34.57 ± 5.49
−11.24 ± 4.32 (−20.02 to −2.46)
0.014
Baseline
Week 4
14.09 ± 2.00
11.14 ± 3.20
Week 8
14.14 ± 1.85
11.71 ± 3.26
0.039 ± 1.99 (−4.01 to 4.088)
0.99
Gastrointestinal tract
9.91 ± 1.82
11.79 ± 2.94
−3.85 ± 2.29 (−8.50 to 0.80)
0.10
Baseline
Week 4
9.95 ± 1.77
4.71 ± 1.39
Week 8
10.27 ± 2.17
6.64 ± 1.69
−1.66 ± 1.86 (−5.44 to 2.12)
0.38
Urinary
7.95 ± 1.92
8.21 ± 1.89
−5.24 ± 1.71 (−8.72 to −1.75)
0.004
Baseline
Week 4
5.36 ± 1.34
6.00 ± 1.90
Week 8
5.95 ± 1.69
7.71 ± 1.75
−1.14 ± 1.25 (−3.67 to 1.40)
0.37
Miscellaneous
4.77 ± 1.69
7.5 ± 1.69
−2.17 ± 1.38 (−4.98 to 0.65)
0.13
Baseline
Week 4
9.00 ± 2.20
5.14 ± 2.09
Week 8
10.32 ± 2.31
8.14 ± 2.09
−1.00 ± 2.11 (−5.29 to 3.29)
0.64
10.73 ± 2.30
7.07 ± 1.65
0.505 ± 1.83 (−3.22 to 4.23)
0.79
Data are expressed in the format of mean ± SEM; the mean difference was derived through adjusting for baseline assessments of treatment and control group; † value was derived by ANCOVA.
